Search results
Results from the WOW.Com Content Network
It is characterized by having high levels of a circulating antibody, immunoglobulin M (IgM), which is made and secreted by the cells involved in the disease. Waldenström macroglobulinemia is an "indolent lymphoma" (i.e., one that tends to grow and spread slowly) and a type of lymphoproliferative disease which shares clinical characteristics ...
NX-5948 is an orally bioavailable, brain penetrant degrader of Bruton’s tyrosine kinase (BTK) which is currently being evaluated in adults for the treatment of relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia or small lymphocytic lymphoma (r/r CLL/SLL) and Waldenstrom’s macroglobulinemia (WM).
NX-5948 demonstrated robust clinical activity with objective responses observed in 7 of 9 (77.8%) evaluable Waldenstrom’s patients in the ongoing Phase 1a/1b clinical trial. Responses are durable and deepen over time with two patients on treatment for greater than one year
Zanubrutinib, sold under the brand name Brukinsa, is an anticancer medication used for the treatment of mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM), marginal zone lymphoma (MZL), and chronic lymphocytic leukemia (CLL).
Bing–Neel syndrome (BNS) is an extremely rare neurologic complication of Waldenström macroglobulinemia (WM), which is a chronic lymphoproliferative disorder. [1] There's no clear definition of BNS but what is known so far is that unlike WM, It involves the central nervous system (CNS), infiltrated by differentiated malignant B cells and by having hyperglobulinemia. [2]
It was approved by the US Food and Drug Administration (FDA) in November 2013, for the treatment of mantle cell lymphoma. [10] In February 2014, the FDA expanded the approved use of ibrutinib to chronic lymphocytic leukemia (CLL). [25] [26] It was approved for Waldenström's macroglobulinemia in 2015. [11] [27]
What is Waldenström's macroglobulinemia? ... The disease is rare — there are about 3 cases per million people per year in the U.S., according to ACS. About 1,000 to 1,500 Americans are ...
Macroglobulinemia is the presence of increased levels of macroglobulins in the circulating blood. It is a plasma cell dyscrasia, resembling leukemia, with cells of lymphocytic, plasmacytic, or intermediate morphology, which secrete a monoclonal immunoglobulin M component. There is diffuse infiltration by the malignant cells of the bone marrow ...